Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:03:45.378Z.
Calculation as of: 2026-10-06T16:03:45.378Z.
Quote observation: 2026-10-06T16:00:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: caaf80bca5ccea9457018b34cf7693b2821ca050e30c360cba938cf84e67b366
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
LB Pharmaceuticals Inc Common Stock
Market Cap
$1.00B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$993.24M
EV/FCF Ratio
N/A
TTM Avg
19.90x
3Y Avg
19.90x
5Y Avg
19.90x
Market Cap
$991.53M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$988.29M
EV/FCF Ratio
6.65x
TTM Avg
9.54x
3Y Avg
10.29x
5Y Avg
18.38x
Market Cap
$1.02B
EV/FCF Ratio
60.49x
TTM Avg
62.48x
3Y Avg
62.48x
5Y Avg
62.48x
Market Cap
$1.03B
EV/FCF Ratio
N/A
TTM Avg
99.90x
3Y Avg
55.01x
5Y Avg
50.88x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $1.00B | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.01B | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $993.24M | N/A | 19.90x | 19.90x | 19.90x |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $991.53M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $988.29M | 6.65x | 9.54x | 10.29x | 18.38x |
| Aktis Oncology, Inc. (AKTS)vs › | $983.49M | N/A | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 60.49x | 62.48x | 62.48x | 62.48x |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | N/A | 99.90x | 55.01x | 50.88x |
| Immatics N.V. (IMTX)vs › | $1.04B | N/A | 4.12x | 4.43x | 22.97x |
| Kura Oncology, Inc. (KURA)vs › | $956.88M | N/A | 6.09x | 6.07x | 6.07x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
